Akanda Corp. (NASDAQ: AKAN) Stock Competitors & Peer Comparison
See AKAN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for AKAN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AKAN | $1.20 | -8.40% | 2.9M | -0.03 | -$44.79 | N/A |
| TAK | $19.67 | +1.13% | 62.2B | 14.16 | $1.39 | +3.59% |
| TEVA | $41.50 | +0.95% | 48.3B | 14.16 | $2.93 | N/A |
| HLN | $10.13 | +1.91% | 44.5B | 20.71 | $0.49 | +1.96% |
| ZTS | $79.38 | +1.22% | 32.8B | 12.06 | $6.58 | +2.65% |
| VTRS | $18.66 | +2.41% | 21.4B | 7.40 | $2.52 | +2.60% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $23.55 | +0.04% | 11.8B | 22.23 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $13.07 | +1.32% | 10.9B | 27.79 | $0.47 | +0.64% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
AKAN vs TAK Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, TAK has a market cap of 62.2B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while TAK trades at $19.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas TAK's P/E ratio is 14.16. In terms of profitability, AKAN's ROE is +3.92%, compared to TAK's ROE of +0.02%. Regarding short-term risk, AKAN is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
AKAN vs TEVA Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, TEVA has a market cap of 48.3B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while TEVA trades at $41.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas TEVA's P/E ratio is 14.16. In terms of profitability, AKAN's ROE is +3.92%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, AKAN is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check TEVA's competition here
Haleon plc (NYSE: HLN)
AKAN vs HLN Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, HLN has a market cap of 44.5B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while HLN trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas HLN's P/E ratio is 20.71. In terms of profitability, AKAN's ROE is +3.92%, compared to HLN's ROE of +0.10%. Regarding short-term risk, AKAN is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
AKAN vs ZTS Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, ZTS has a market cap of 32.8B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while ZTS trades at $79.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas ZTS's P/E ratio is 12.06. In terms of profitability, AKAN's ROE is +3.92%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, AKAN is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
AKAN vs VTRS Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, VTRS has a market cap of 21.4B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while VTRS trades at $18.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas VTRS's P/E ratio is 7.40. In terms of profitability, AKAN's ROE is +3.92%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, AKAN is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
AKAN vs ITCI Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas ITCI's P/E ratio is -180.64. In terms of profitability, AKAN's ROE is +3.92%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, AKAN is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
AKAN vs ELAN Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, ELAN has a market cap of 11.8B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while ELAN trades at $23.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas ELAN's P/E ratio is 22.23. In terms of profitability, AKAN's ROE is +3.92%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, AKAN is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
AKAN vs CTLT Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas CTLT's P/E ratio is -27.84. In terms of profitability, AKAN's ROE is +3.92%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, AKAN is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
AKAN vs RDY Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, RDY has a market cap of 10.9B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while RDY trades at $13.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas RDY's P/E ratio is 27.79. In terms of profitability, AKAN's ROE is +3.92%, compared to RDY's ROE of +0.09%. Regarding short-term risk, AKAN is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
AKAN vs ALKS Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, ALKS has a market cap of 6.9B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while ALKS trades at $41.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas ALKS's P/E ratio is 43.39. In terms of profitability, AKAN's ROE is +3.92%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, AKAN is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
AKAN vs LNTH Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while LNTH trades at $99.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas LNTH's P/E ratio is 16.76. In terms of profitability, AKAN's ROE is +3.92%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, AKAN is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
AKAN vs AMRX Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, AMRX has a market cap of 6.1B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while AMRX trades at $19.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas AMRX's P/E ratio is 21.31. In terms of profitability, AKAN's ROE is +3.92%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, AKAN is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check AMRX's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
AKAN vs RGC Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, RGC has a market cap of 4.8B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while RGC trades at $9.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas RGC's P/E ratio is -959.00. In terms of profitability, AKAN's ROE is +3.92%, compared to RGC's ROE of -1.61%. Regarding short-term risk, AKAN is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for AKAN.Check RGC's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
AKAN vs INDV Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, INDV has a market cap of 4B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while INDV trades at $32.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas INDV's P/E ratio is 8.89. In terms of profitability, AKAN's ROE is +3.92%, compared to INDV's ROE of -2.16%. Regarding short-term risk, AKAN is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check INDV's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
AKAN vs HCM Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while HCM trades at $14.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas HCM's P/E ratio is 135.88. In terms of profitability, AKAN's ROE is +3.92%, compared to HCM's ROE of +0.01%. Regarding short-term risk, AKAN is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check HCM's competition here
Alvotech (NASDAQ: ALVOW)
AKAN vs ALVOW Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, ALVOW has a market cap of 2.4B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while ALVOW trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas ALVOW's P/E ratio is 37.90. In terms of profitability, AKAN's ROE is +3.92%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, AKAN is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check ALVOW's competition here
Bausch Health Companies Inc. (NYSE: BHC)
AKAN vs BHC Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while BHC trades at $6.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas BHC's P/E ratio is 1.60. In terms of profitability, AKAN's ROE is +3.92%, compared to BHC's ROE of +0.89%. Regarding short-term risk, AKAN is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check BHC's competition here
Perrigo Company plc (NYSE: PRGO)
AKAN vs PRGO Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, PRGO has a market cap of 2.3B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while PRGO trades at $16.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas PRGO's P/E ratio is 6.65. In terms of profitability, AKAN's ROE is +3.92%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, AKAN is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check PRGO's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
AKAN vs DCPH Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas DCPH's P/E ratio is -11.58. In terms of profitability, AKAN's ROE is +3.92%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, AKAN is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check DCPH's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
AKAN vs SUPN Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, SUPN has a market cap of 2.2B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while SUPN trades at $37.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas SUPN's P/E ratio is 12.38. In terms of profitability, AKAN's ROE is +3.92%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, AKAN is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check SUPN's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
AKAN vs AVDL Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, AKAN's ROE is +3.92%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, AKAN is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
AKAN vs EMBCV Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas EMBCV's P/E ratio is N/A. In terms of profitability, AKAN's ROE is +3.92%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, AKAN is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for AKAN.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
AKAN vs DVAX Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas DVAX's P/E ratio is -41.89. In terms of profitability, AKAN's ROE is +3.92%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, AKAN is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
AKAN vs ALVO Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while ALVO trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas ALVO's P/E ratio is -8.47. In terms of profitability, AKAN's ROE is +3.92%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, AKAN is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check ALVO's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
AKAN vs TRLV Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, TRLV has a market cap of 1.7B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while TRLV trades at $10.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas TRLV's P/E ratio is -4.07. In terms of profitability, AKAN's ROE is +3.92%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, AKAN is more volatile compared to TRLV. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check TRLV's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
AKAN vs ANIP Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while ANIP trades at $72.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas ANIP's P/E ratio is 8.79. In terms of profitability, AKAN's ROE is +3.92%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, AKAN is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
AKAN vs TARO Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas TARO's P/E ratio is 30.05. In terms of profitability, AKAN's ROE is +3.92%, compared to TARO's ROE of +0.03%. Regarding short-term risk, AKAN is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
AKAN vs PAHC Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while PAHC trades at $38.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas PAHC's P/E ratio is 13.25. In terms of profitability, AKAN's ROE is +3.92%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, AKAN is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check PAHC's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
AKAN vs PCRX Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, PCRX has a market cap of 1.4B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while PCRX trades at $36.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas PCRX's P/E ratio is 13.98. In terms of profitability, AKAN's ROE is +3.92%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, AKAN is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check PCRX's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
AKAN vs ETON Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, ETON has a market cap of 1.4B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while ETON trades at $50.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas ETON's P/E ratio is 132.34. In terms of profitability, AKAN's ROE is +3.92%, compared to ETON's ROE of +0.40%. Regarding short-term risk, AKAN is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check ETON's competition here
Cronos Group Inc. (NASDAQ: CRON)
AKAN vs CRON Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while CRON trades at $3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas CRON's P/E ratio is 16.44. In terms of profitability, AKAN's ROE is +3.92%, compared to CRON's ROE of +0.06%. Regarding short-term risk, AKAN is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
AKAN vs AMPH Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while AMPH trades at $25.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas AMPH's P/E ratio is 8.83. In terms of profitability, AKAN's ROE is +3.92%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, AKAN is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
AKAN vs HROW Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, HROW has a market cap of 1B. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while HROW trades at $27.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas HROW's P/E ratio is -27.56. In terms of profitability, AKAN's ROE is +3.92%, compared to HROW's ROE of -1.04%. Regarding short-term risk, AKAN is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check HROW's competition here
PetIQ, Inc. (NASDAQ: PETQ)
AKAN vs PETQ Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas PETQ's P/E ratio is 83.73. In terms of profitability, AKAN's ROE is +3.92%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, AKAN is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
AKAN vs COLL Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, COLL has a market cap of 755M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while COLL trades at $23.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas COLL's P/E ratio is 2.91. In terms of profitability, AKAN's ROE is +3.92%, compared to COLL's ROE of +0.16%. Regarding short-term risk, AKAN is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
AKAN vs IRWD Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, IRWD has a market cap of 578.3M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while IRWD trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas IRWD's P/E ratio is 4.49. In terms of profitability, AKAN's ROE is +3.92%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, AKAN is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
AKAN vs BDSI Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas BDSI's P/E ratio is 6.82. In terms of profitability, AKAN's ROE is +3.92%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, AKAN is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check BDSI's competition here
Evotec SE (NASDAQ: EVO)
AKAN vs EVO Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, EVO has a market cap of 491.9M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while EVO trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas EVO's P/E ratio is -1.96. In terms of profitability, AKAN's ROE is +3.92%, compared to EVO's ROE of -0.27%. Regarding short-term risk, AKAN is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check EVO's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
AKAN vs AQST Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, AQST has a market cap of 473.8M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while AQST trades at $3.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas AQST's P/E ratio is -5.81. In terms of profitability, AKAN's ROE is +3.92%, compared to AQST's ROE of +2.44%. Regarding short-term risk, AKAN is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check AQST's competition here
Evolus, Inc. (NASDAQ: EOLS)
AKAN vs EOLS Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, EOLS has a market cap of 468.3M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while EOLS trades at $7.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas EOLS's P/E ratio is -22.45. In terms of profitability, AKAN's ROE is +3.92%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, AKAN is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check EOLS's competition here
Kamada Ltd. (NASDAQ: KMDA)
AKAN vs KMDA Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, KMDA has a market cap of 446.6M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while KMDA trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas KMDA's P/E ratio is 20.37. In terms of profitability, AKAN's ROE is +3.92%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, AKAN is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
AKAN vs TKNO Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, TKNO has a market cap of 380.1M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while TKNO trades at $7.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas TKNO's P/E ratio is -22.84. In terms of profitability, AKAN's ROE is +3.92%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, AKAN is more volatile compared to TKNO. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check TKNO's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
AKAN vs TLRY Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, TLRY has a market cap of 340M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while TLRY trades at $3.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas TLRY's P/E ratio is -2.17. In terms of profitability, AKAN's ROE is +3.92%, compared to TLRY's ROE of -0.09%. Regarding short-term risk, AKAN is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check TLRY's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
AKAN vs EBS Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, EBS has a market cap of 326.9M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while EBS trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas EBS's P/E ratio is 4.43. In terms of profitability, AKAN's ROE is +3.92%, compared to EBS's ROE of -0.36%. Regarding short-term risk, AKAN is more volatile compared to EBS. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check EBS's competition here
Canopy Growth Corporation (NASDAQ: CGC)
AKAN vs CGC Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, CGC has a market cap of 301.7M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while CGC trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas CGC's P/E ratio is -1.60. In terms of profitability, AKAN's ROE is +3.92%, compared to CGC's ROE of -0.33%. Regarding short-term risk, AKAN is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check CGC's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
AKAN vs ALIM Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas ALIM's P/E ratio is 5.28. In terms of profitability, AKAN's ROE is +3.92%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, AKAN is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check ALIM's competition here
Glass House Brands Inc (NYSE: GLAS)
AKAN vs GLAS Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, GLAS has a market cap of 279.8M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while GLAS trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas GLAS's P/E ratio is -5.68. In terms of profitability, AKAN's ROE is +3.92%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, AKAN is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for AKAN.Check GLAS's competition here
Landec Corporation (NASDAQ: LNDC)
AKAN vs LNDC Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas LNDC's P/E ratio is -4.04. In terms of profitability, AKAN's ROE is +3.92%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, AKAN is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
AKAN vs ACB Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, ACB has a market cap of 252.6M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while ACB trades at $3.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas ACB's P/E ratio is -2.88. In terms of profitability, AKAN's ROE is +3.92%, compared to ACB's ROE of -0.21%. Regarding short-term risk, AKAN is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check ACB's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
AKAN vs LFCR Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, LFCR has a market cap of 241.8M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while LFCR trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas LFCR's P/E ratio is -5.02. In terms of profitability, AKAN's ROE is +3.92%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, AKAN is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
AKAN vs TYHT Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas TYHT's P/E ratio is -1.61. In terms of profitability, AKAN's ROE is +3.92%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, AKAN is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
AKAN vs SIGA Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, SIGA has a market cap of 227.8M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while SIGA trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas SIGA's P/E ratio is 11.74. In terms of profitability, AKAN's ROE is +3.92%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, AKAN is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check SIGA's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
AKAN vs REPH Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas REPH's P/E ratio is -8.04. In terms of profitability, AKAN's ROE is +3.92%, compared to REPH's ROE of -0.22%. Regarding short-term risk, AKAN is more volatile compared to REPH. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check REPH's competition here
Theratechnologies Inc. (NASDAQ: THTX)
AKAN vs THTX Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas THTX's P/E ratio is -28.83. In terms of profitability, AKAN's ROE is +3.92%, compared to THTX's ROE of +0.36%. Regarding short-term risk, AKAN is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
AKAN vs ASRT Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas ASRT's P/E ratio is -7.10. In terms of profitability, AKAN's ROE is +3.92%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, AKAN is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check ASRT's competition here
Journey Medical Corporation (NASDAQ: DERM)
AKAN vs DERM Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, DERM has a market cap of 139.9M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while DERM trades at $4.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas DERM's P/E ratio is -22.52. In terms of profitability, AKAN's ROE is +3.92%, compared to DERM's ROE of -0.20%. Regarding short-term risk, AKAN is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
AKAN vs CRDL Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, CRDL has a market cap of 132.7M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while CRDL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas CRDL's P/E ratio is -4.38. In terms of profitability, AKAN's ROE is +3.92%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, AKAN is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check CRDL's competition here
Organigram Global Inc. (NASDAQ: OGI)
AKAN vs OGI Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, OGI has a market cap of 130.9M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while OGI trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas OGI's P/E ratio is 2.09. In terms of profitability, AKAN's ROE is +3.92%, compared to OGI's ROE of +0.21%. Regarding short-term risk, AKAN is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check OGI's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
AKAN vs ORGO Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, ORGO has a market cap of 128.6M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while ORGO trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas ORGO's P/E ratio is 33.32. In terms of profitability, AKAN's ROE is +3.92%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, AKAN is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for AKAN.Check ORGO's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
AKAN vs SCTL Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas SCTL's P/E ratio is -7.86. In terms of profitability, AKAN's ROE is +3.92%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, AKAN is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
AKAN vs BGM Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, BGM has a market cap of 110.3M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while BGM trades at $8.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas BGM's P/E ratio is -1.81. In terms of profitability, AKAN's ROE is +3.92%, compared to BGM's ROE of -0.05%. Regarding short-term risk, AKAN is more volatile compared to BGM. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check BGM's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
AKAN vs CPIX Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, CPIX has a market cap of 107.6M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while CPIX trades at $7.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas CPIX's P/E ratio is -17.95. In terms of profitability, AKAN's ROE is +3.92%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, AKAN is more volatile compared to CPIX. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check CPIX's competition here
Procaps Group S.A. (NASDAQ: PROC)
AKAN vs PROC Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas PROC's P/E ratio is 1.53. In terms of profitability, AKAN's ROE is +3.92%, compared to PROC's ROE of -2.22%. Regarding short-term risk, AKAN is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
AKAN vs OPTN Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas OPTN's P/E ratio is -4.42. In terms of profitability, AKAN's ROE is +3.92%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, AKAN is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
AKAN vs ZOM Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas ZOM's P/E ratio is -1.62. In terms of profitability, AKAN's ROE is +3.92%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, AKAN is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
AKAN vs GRVI Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas GRVI's P/E ratio is 26.05. In terms of profitability, AKAN's ROE is +3.92%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, AKAN is more volatile compared to GRVI. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
AKAN vs ZYNE Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, AKAN's ROE is +3.92%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, AKAN is more volatile compared to ZYNE. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check ZYNE's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
AKAN vs ZYBT Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, ZYBT has a market cap of 69.2M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while ZYBT trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas ZYBT's P/E ratio is -7.30. In terms of profitability, AKAN's ROE is +3.92%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, AKAN is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for AKAN.Check ZYBT's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
AKAN vs SSIC Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas SSIC's P/E ratio is 11.93. In terms of profitability, AKAN's ROE is +3.92%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, AKAN is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
AKAN vs VLNS Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas VLNS's P/E ratio is -1.03. In terms of profitability, AKAN's ROE is +3.92%, compared to VLNS's ROE of N/A. Regarding short-term risk, AKAN is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
AKAN vs DRRX Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas DRRX's P/E ratio is -4.44. In terms of profitability, AKAN's ROE is +3.92%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, AKAN is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check DRRX's competition here
Talphera, Inc. (NASDAQ: TLPH)
AKAN vs TLPH Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, TLPH has a market cap of 56.1M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while TLPH trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas TLPH's P/E ratio is -4.00. In terms of profitability, AKAN's ROE is +3.92%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, AKAN is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check TLPH's competition here
InterCure Ltd. (NASDAQ: INCR)
AKAN vs INCR Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, INCR has a market cap of 54.1M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while INCR trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas INCR's P/E ratio is -4.81. In terms of profitability, AKAN's ROE is +3.92%, compared to INCR's ROE of -0.09%. Regarding short-term risk, AKAN is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
AKAN vs JUPW Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas JUPW's P/E ratio is -2.41. In terms of profitability, AKAN's ROE is +3.92%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, AKAN is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for AKAN.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
AKAN vs QLI Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas QLI's P/E ratio is -4.92. In terms of profitability, AKAN's ROE is +3.92%, compared to QLI's ROE of -0.16%. Regarding short-term risk, AKAN is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
AKAN vs HEXO Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas HEXO's P/E ratio is -0.26. In terms of profitability, AKAN's ROE is +3.92%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, AKAN is more volatile compared to HEXO. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
AKAN vs RMTI Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, RMTI has a market cap of 29.9M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while RMTI trades at $7.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas RMTI's P/E ratio is -5.54. In terms of profitability, AKAN's ROE is +3.92%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, AKAN is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check RMTI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
AKAN vs CPHI Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, CPHI has a market cap of 29.4M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while CPHI trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas CPHI's P/E ratio is -1.59. In terms of profitability, AKAN's ROE is +3.92%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, AKAN is more volatile compared to CPHI. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check CPHI's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
AKAN vs SHPH Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, SHPH has a market cap of 24.3M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while SHPH trades at $5.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas SHPH's P/E ratio is -0.24. In terms of profitability, AKAN's ROE is +3.92%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, AKAN is more volatile compared to SHPH. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check SHPH's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
AKAN vs CYTH Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas CYTH's P/E ratio is -0.80. In terms of profitability, AKAN's ROE is +3.92%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, AKAN is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check CYTH's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
AKAN vs AYTU Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, AYTU has a market cap of 22.1M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while AYTU trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas AYTU's P/E ratio is -1.72. In terms of profitability, AKAN's ROE is +3.92%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, AKAN is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
AKAN vs TXMD Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, TXMD has a market cap of 22M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while TXMD trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas TXMD's P/E ratio is 96.79. In terms of profitability, AKAN's ROE is +3.92%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, AKAN is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check TXMD's competition here
Optimi Health Corp. (NASDAQ: OPTH)
AKAN vs OPTH Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, OPTH has a market cap of 19.4M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while OPTH trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas OPTH's P/E ratio is -2.17. In terms of profitability, AKAN's ROE is +3.92%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, AKAN is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check OPTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
AKAN vs EVOK Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas EVOK's P/E ratio is -7.97. In terms of profitability, AKAN's ROE is +3.92%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, AKAN is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check EVOK's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
AKAN vs ACRX Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas ACRX's P/E ratio is -0.31. In terms of profitability, AKAN's ROE is +3.92%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, AKAN is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for AKAN.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
AKAN vs CABR Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, CABR has a market cap of 11.2M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while CABR trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas CABR's P/E ratio is -1.58. In terms of profitability, AKAN's ROE is +3.92%, compared to CABR's ROE of -3.86%. Regarding short-term risk, AKAN is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for AKAN.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
AKAN vs AGRX Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas AGRX's P/E ratio is -0.89. In terms of profitability, AKAN's ROE is +3.92%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, AKAN is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
AKAN vs NLTX Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas NLTX's P/E ratio is -0.28. In terms of profitability, AKAN's ROE is +3.92%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, AKAN is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
AKAN vs LCI Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas LCI's P/E ratio is -0.04. In terms of profitability, AKAN's ROE is +3.92%, compared to LCI's ROE of +1.66%. Regarding short-term risk, AKAN is more volatile compared to LCI. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
AKAN vs ADMP Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas ADMP's P/E ratio is -0.08. In terms of profitability, AKAN's ROE is +3.92%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, AKAN is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check ADMP's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
AKAN vs INM Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, INM has a market cap of 7.3M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while INM trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas INM's P/E ratio is -0.43. In terms of profitability, AKAN's ROE is +3.92%, compared to INM's ROE of -1.35%. Regarding short-term risk, AKAN is more volatile compared to INM. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check INM's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
AKAN vs SNOA Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, SNOA has a market cap of 5.5M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while SNOA trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas SNOA's P/E ratio is -1.04. In terms of profitability, AKAN's ROE is +3.92%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, AKAN is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check SNOA's competition here
Mallinckrodt plc (AMEX: MNK)
AKAN vs MNK Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas MNK's P/E ratio is -0.44. In terms of profitability, AKAN's ROE is +3.92%, compared to MNK's ROE of -0.36%. Regarding short-term risk, AKAN is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for AKAN.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
AKAN vs FLGC Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas FLGC's P/E ratio is -0.19. In terms of profitability, AKAN's ROE is +3.92%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, AKAN is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for AKAN.Check FLGC's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
AKAN vs GELS Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, GELS has a market cap of 4.2M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while GELS trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas GELS's P/E ratio is -1.05. In terms of profitability, AKAN's ROE is +3.92%, compared to GELS's ROE of -0.25%. Regarding short-term risk, AKAN is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for AKAN.Check GELS's competition here
cbdMD, Inc. (AMEX: YCBD)
AKAN vs YCBD Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, YCBD has a market cap of 3.8M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while YCBD trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas YCBD's P/E ratio is -0.84. In terms of profitability, AKAN's ROE is +3.92%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, AKAN is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check YCBD's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
AKAN vs PLXP Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas PLXP's P/E ratio is -0.22. In terms of profitability, AKAN's ROE is +3.92%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, AKAN is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for AKAN.Check PLXP's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
AKAN vs UPC Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, UPC has a market cap of 2.5M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while UPC trades at $3.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas UPC's P/E ratio is -0.49. In terms of profitability, AKAN's ROE is +3.92%, compared to UPC's ROE of -0.03%. Regarding short-term risk, AKAN is more volatile compared to UPC. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check UPC's competition here
Athenex, Inc. (NASDAQ: ATNX)
AKAN vs ATNX Comparison October 2026
Akanda Corp. (NASDAQ: AKAN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 2.9M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, AKAN is priced at $1.20 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -0.03, whereas ATNX's P/E ratio is -0.02. In terms of profitability, AKAN's ROE is +3.92%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, AKAN is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for AKAN.Check ATNX's competition here